SCHEMBL2877666

SCHEMBL2877666

Cn1cc(Br)c2ccncc21

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 7/20 0.59
NFATC1 O95644 4/20 0.59
GSK3B P49841 4/20 0.59
PDPK1 O15530 1/20 0.46
TGFBR1 P36897 1/20 0.46
IKBKE Q14164 1/20 0.46
TBK1 Q9UHD2 1/20 0.46
HASPIN Q8TF76 2/20 0.41
DYRK1B Q9Y463 1/20 0.39
AXL P30530 1/20 0.39
KCNH2 Q12809 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
KDM5A P29375 1/20 0.36
IMPDH2 P12268 1/20 0.34
MAP3K5 Q99683 1/20 0.34
CMA1 P23946 1/20 0.34
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12918543 0.78 DYRK1A (0.61) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL4858180 0.78 DYRK1A (0.46) DYRK1ANFATC1GSK3BKCNH2ADORA3
SCHEMBL20674193 0.77 DYRK1A (0.59) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL31227905 0.77 DYRK1A (0.59) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL15388885 0.77 HASPIN (0.61) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL20385498 0.77 DYRK1A (0.59) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL21917172 0.77 DYRK1A (0.62) DYRK1ANFATC1GSK3BPDPK1TGFBR1
SCHEMBL4855717 0.77 DYRK1A (0.43) DYRK1ANFATC1GSK3BDYRK1BAXL
SCHEMBL21224912 0.77 BRD4 (0.45) DYRK1ANFATC1GSK3BTGFBR1AXL
SCHEMBL16651223 0.77 BRD4 (0.46) DYRK1ANFATC1GSK3BTGFBR1AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2025-02-27 US disclosed
EP-4444420-A2 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
EP-3801499-B1 INHIBITORS OF SARM1 DISARM THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20230391752-A1 PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES CHULALONGKORN UNIVERSITY (TH) 2023-12-07 US disclosed
WO-2023107723-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
WO-2023107723-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
WO-2023280283-A1 COMPOUND USED AS SHP2 INHIBITOR AND USE THEREOF 浙江同源康医药股份有限公司 2023-01-12 WO disclosed
US-20220194933-A1 INHIBITORS OF SARM1 DISARM THERAPEUTICS, INC. 2022-06-23 US disclosed
WO-2022087422-A9 PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES CHULALONGKORN UNIVERSITY (TH) 2022-06-09 WO disclosed
WO-2022087422-A1 PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES CHULALONGKORN UNIVERSITY (TH) 2022-04-28 WO disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
EP-2855477-A1 ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS Merck Sharp & Dohme Corp. (US) 2015-04-08 EP disclosed
WO-2013181075-A1 ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2013-12-05 WO disclosed
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391752-A1 PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES GLS2, PYGL, CPS1 DYRK1A 4824/4885NFATC1 2613/4885GSK3B 3134/4885
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MC1R, MCHR1, MCHR2 DYRK1A 436/4885NFATC1 4734/4885GSK3B 1829/4885
US-20220194933-A1 INHIBITORS OF SARM1 SARM1, SMN1; SMN2, SARNP DYRK1A 3924/4885NFATC1 2325/4885GSK3B 2202/4885
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MAPT, SLC14A1, UBTF DYRK1A 2261/4885NFATC1 3349/4885GSK3B 226/4885
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DYRK2, DYRK1A, PYGB DYRK1A 2/4885NFATC1 2185/4885GSK3B 46/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 DYRK1A 1117/4885NFATC1 1618/4885GSK3B 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.